Research Triangle Institute

Rangan Maitra

Scott P Runyon

Sanju Narayanan

James Barnwell Thomas

Kenneth S Rehder

Yanan Zhang

Srinivas Olepu

Alan Bradley Fulp

Herbert H Seltzman

George Salvatore Amato

Robert William Wiethe

This disclosure is directed to agonists of the apelin receptor (APJ) with heterocyclic cores and uses of such agonists.

Heterocyclic apelin receptor (APJ) agonists and uses thereof

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

Apelin receptor (APJ) agonists and uses thereof

This disclosure is directed to various compounds and methods of preparation of improved compounds that are capable of functioning as cannabinoid receptor 1 (CB1) antagonists with reduced central nervous system (CNS) side effects. The application is also directed to pharmaceutical compositions containing one or more of these compounds, which may also contain one or more additional therapeutic agents. It is also directed to methods of treatment of various conditions that may be responsive to antagonism of the CB1 receptors, including, but not limited to, metabolic syndromes (including liver disease, obesity, and diabetes).

Diaryl purine derivatives with improved bioavailability

The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation.

Peripherally restricted diphenyl purine derivatives

The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation. 

Growing community of inventors

Cary, NC, United States of America

Rangan Maitra